Moderna and Merck said Tuesday that their experimental, personalized vaccine continued to reduce the risk of death or recurrence of the most deadly skin cancer, five years after treatment started.In a mid-stage study of high-risk melanoma patients who had undergone surgery, the vaccine in combination with Merck’s Keytruda reduced the risk of recurrence or death […]
